Cardiac Rhythm Management Devices – Market Insights – United States

The landscape of the US cardiac rhythm management device market is poised for dynamic change through 2033, with trends varying by device segment. The increasing adoption of innovative devices such as leadless pacemakers is driving market growth, with these devices gaining traction as the new standard of care. In particular, the entry of the Aveir DR leadless dual-chamber pacemaker has significantly expanded the population eligible for treatment with a pacemaker.

This Medtech 360 Report provides comprehensive data and analysis on the state of the US cardiac rhythm management device market from 2019 through 2033.

The adoption of innovative devices will offset weakening revenue for traditional CRM devices.

What level of market penetration is forecasted for novel devices like leadless pacemakers and S-ICDs?

With the predicted uptake of such novel devices, how will their adoption impact the revenues of traditional CRM devices?

Following the approval of Aveir DR, what factors are likely to influence the uptake of leadless dual-chamber pacemakers?

The generation of clinical data will be an important competitive factor for disruptive CRM devices.

Which regulatory and reimbursement changes are expected due to clinical evidence?

How has clinical data offset negative press and physician perception of market competitors?

How will the market share dynamics of different device segments be altered by ongoing clinical trials?

Some segments of the CRM device market are mature and highly saturated, spurring competitors to innovate to achieve growth.

How can individual competitors realize growth in this large but saturated market?

How do epidemiological trends and new technologies influence growth in different product segments?

How will the market change with the recent approval of the first leadless dual-chamber pacemaker?

Will mergers and acquisitions play a key role in this device market?